Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator

[1]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[2]  A. Camm,et al.  Optimising the dichotomy limit for left ventricular ejection fraction in selecting patients for defibrillator therapy after myocardial infarction , 2007, Heart.

[3]  Avi Sabbag,et al.  Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry. , 2015, Heart rhythm.

[4]  J. Roovers.  Registries: what level of evidence do they provide? , 2007, International Urogynecology Journal.

[5]  M. Wolbers,et al.  Death Without Prior Appropriate Implantable Cardioverter-Defibrillator Therapy: A Competing Risk Study , 2008, Circulation.

[6]  A. Moss,et al.  Long-Term Clinical Course of Patients After Termination of Ventricular Tachyarrhythmia by an Implanted Defibrillator , 2004, Circulation.

[7]  P. Austin,et al.  Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators , 2015, Circulation. Heart failure.

[8]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[9]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[10]  R. Cappato,et al.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). , 2000, Circulation.

[11]  H. Heidbuchel,et al.  Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  A. Moss,et al.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. , 2008, Journal of the American College of Cardiology.

[13]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[14]  Michael R Gold,et al.  Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. , 2007, Journal of the American College of Cardiology.

[15]  D. Lin,et al.  Acute Hemodynamic Decompensation During Catheter Ablation of Scar-Related Ventricular Tachycardia: Incidence, Predictors, and Impact on Mortality , 2014, Circulation. Arrhythmia and electrophysiology.

[16]  Tim Smith,et al.  The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. , 2013, European heart journal.

[17]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[18]  V L Gott,et al.  Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. , 1980, The New England journal of medicine.

[19]  H. Krumholz.  Registries and selection bias: the need for accountability. , 2009, Circulation. Cardiovascular quality and outcomes.

[20]  Jeroen J. Bax,et al.  Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score , 2012, Heart.

[21]  Sana M. Al-Khatib,et al.  Non-evidence-based ICD implantations in the United States. , 2011, JAMA.

[22]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[23]  A. Moss,et al.  Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator: An Extended 8-Year Follow-Up Study of the Multicenter Automatic Defibrillator Implantation Trial II , 2010, Circulation.

[24]  A. Tsiatis,et al.  Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.

[25]  D. Mark,et al.  Prognostic importance of defibrillator shocks in patients with heart failure. , 2008, The New England journal of medicine.

[26]  Alvin I Mushlin,et al.  The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. , 2006, Journal of the American College of Cardiology.

[27]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[28]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[29]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[30]  G. Boriani,et al.  Cost-effectiveness of implantable cardioverter-defibrillators. , 2001, European heart journal.

[31]  Judy A Shea,et al.  Costs and quality-of-life effects of implantable cardioverter-defibrillators. , 2006, The American journal of cardiology.

[32]  Karen L. Gunson,et al.  Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. , 2006, Journal of the American College of Cardiology.

[33]  E. Arbustini,et al.  The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[34]  A. Laupacis,et al.  Design and implementation of a population-based registry of Implantable Cardioverter Defibrillators (ICDs) in Ontario. , 2008, Heart rhythm.

[35]  M. Josephson,et al.  A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. , 2008, Journal of the American College of Cardiology.

[36]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[37]  M Gent,et al.  Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study , 2001, Circulation.

[38]  L. Dekker,et al.  Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest? , 2009, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[39]  M. Brignole.  Are complications of implantable defibrillators under-estimated and benefits over-estimated? , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.